"That's why we are also excited to announce that the company will continue to fund the UCB U.S. Myasthenia Gravis Scholarship into 2026." "Financially, I face significant challenges as I juggle ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

ATLANTA, June 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB ...

"That's why we are also excited to announce that the company will continue to fund the UCB U.S. Myasthenia Gravis Scholarship into 2026." "Financially, I face significant challenges as I juggle the ...

OTTAWA — Established treatments such as thymectomy and steroids remain mainstays in the management of myasthenia gravis (MG), according to a presentation at the Canadian Neurological Sciences ...

MG is an acquired antibody-mediated rare autoimmune disorder affecting the neuromuscular junction. According to the Myasthenia Gravis Foundation of America (MGFA) and various studies, its global ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

Myasthenia Gravis (MG) is a rare neurological disorder that severely impairs muscle movement and can lead to life-threatening complications. While existing C5 inhibitors have contributed to ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.